anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an application of a nuclear receptor Rev-erb alpha in preparing antiplatelet drugs, wherein the amino acid sequence of the nuclear receptor Rev-erb alpha is shown as SEQ ID NO. 2. The invention also provides application of the Rev-erb alpha inhibitor in preparing a medicament for inhibiting platelet activity. The present invention demonstrates the presence of the nuclear receptor Rev-erb α in human and mouse platelets. The functional deletion of Rev-erb alpha in vivo can prolong the bleeding time and inhibit the carotid artery thrombosis induced by ferric chloride. It was found that Rev-erb α, either genetically deleted or pharmacologically inactivated, inhibits ADP pathway mediated platelet aggregation. The Rev-erb α inhibitor SR8278 significantly reduces the release of α granules upon ADP-induced platelet activation. The role of the nuclear receptor Rev-erb α is exerted by inhibiting ADP pathway mediated platelet activation and granule release following activation.
Innate lymphoid cells (ILCs) are involved in the innate immune system because they lack specific antigen receptors and lineage markers. ILCs also display phenotypic and characteristic features of adaptive immune cells. Therefore, ILCs are functional in essential interactions between adaptive and innate immunity. ILCs are found in both lymphoid and nonlymphoid tissues and migrate to the area of inflammation during the inflammatory process. ILCs respond to pathogens by producing a variety of cytokines and are involved in the barrier defense of antigens and in many immunological processes such as allergic events. Recent research has shown that ILCs are functional during human pregnancy and have been suggested to be essential for the healthy progression of pregnancy. In this review, we focus on the role of ILCs in human pregnancy by discussing the relationship between ILCs and the pregnancy microenvironment, specifically summarizing the role of ILCs in physiological and pathological pregnancies.
The invention provides a long-acting human recombinant glucagon-like peptide-1 and application thereof, wherein wild GLP-1 is subjected to mutation modification so as not to be sheared by DPP-4 enzyme, and a sequence containing one or more CTP is connected to the N end or/and the C end of the mutant GLP-1; the GLP-1 wild type amino acid sequence is shown as SEQ ID NO. 1; the amino acid sequence of the GLP-1 variant is shown as SEQ ID NO. 2; the amino acid sequence of the CTP is shown as SEQ ID NO. 3. Means were developed for long acting human glucagon-like peptide-1 linked to the coding sequence of mutant glucagon-like peptide-1 through the sequence of hcgβ Carboxy Terminal Peptide (CTP). Analogs were designed by ligating one or more CTP sequences to the C-terminus or/and the N-terminus of GLP-1.
Four prospective randomized studies, three U.S. and one Italian, have been conducted to compare the efficacy and safety of idarubicin (IDR) to that of daunorubicin (DNR), each in combination with cytarabine as induction therapy in previously untreated adult patients with acute myeloid leukemia (AML). These data are summarized in the following table and demonstrate significantly greater complete remission rates for the IDR regimen in two of the three U.S. studies and significantly longer overall survival for the IDR regimen in two of the three U.S. studies. 

There is no consensus regarding optional regimens to be used for consolidation; however, the following consolidation regimens were used in U.S. controlled trials. Patients received the same anthracycline for consolidation as was used for induction.

Studies 1 and 3 utilized 2 courses of consolidation therapy consisting of idarubicin 12 or 13 mg/m2 daily for 2 days, respectively (or DNR 50 or 45 mg/m2 daily for 2 days), and cytarabine, either 25 mg/m2 by IV bolus followed by 200 mg/m2 daily by continuous infusion for 4 days (Study 1), or 100 mg/m2 daily for 5 days by continuous infusion (Study 3). A rest period of 4 to 6 weeks is recommended prior to initiation of consolidation and between the courses. Hematologic recovery is mandatory prior to initiation of each consolidation course.

Study 2 utilized 3 consolidation courses, administered at intervals of 21 days or upon hematologic recovery. Each course consisted of idarubicin 15 mg/m2 IV for 1 dose (or DNR 50 mg/m2 IV for 1 dose), cytarabine 100 mg/m2 every 12 hours for 10 doses and 6-thioguanine 100 mg/m2 orally for 10 doses. If severe myelosuppression occurred, subsequent courses were given with 25% reduction in the doses of all drugs. In addition, this study included 4 courses of maintenance therapy (2 days of the same anthracycline as was used in induction and 5 days of cytarabine).

Toxicities and duration of aplasia were similar during induction on the 2 arms in the U.S. studies except for an increase in mucositis on the IDR arm in one study. During consolidation, duration of aplasia on the IDR arm was longer in all three studies and mucositis was more frequent in two studies. During consolidation, transfusion requirements were higher on the IDR arm in the two studies in which they were tabulated, and patients on the IDR arm in Study 3 spent more days on IV antibiotics (Study 3 used a higher dose of idarubicin).

The benefit of consolidation and maintenance therapy in prolonging the duration of remission and survival is not proven.

Intensive maintenance with idarubicin is not recommended in view of the considerable toxicity (including deaths in remission) experienced by patients during the maintenance phase of Study 2.

A higher induction death rate was noted in patients on the IDR arm in the Italian trial. Since this was not noted in patients of similar age in the U.S. trials, one may speculate that it was due to a difference in the level of supportive care.
Provided is a novel Lactobacillus plantarum NBM-01-07-003. The scientific name thereof is: Lactobacillus plantarum subsp. plantarum NBM-01-07-003; the preservation unit is: China General Microbiological Culture Collection Center; the address is: No. 3 Institute of Microbiology, Chinese Academy of Sciences, No. 1 Beichen West Road, Chaoyang District, Beijing; the preservation date is: 4 September 2018; and the preservation number is: CGMCC No.16417. The novel Lactobacillus plantarum NBM-01-07-003 has the use of adsorbing metal, and can achieve the effect of preventing or/and treating metal poisoning or complications related thereto.
Pogo transposable element-derived protein with ZNF domain (POGZ) gene encodes a chromatin regulator and rare variants on this gene have been associated with a broad spectrum of neurodevelopmental disorders, such as White-Sutton syndrome. Patient clinical manifestations frequently include developmental delay, autism spectrum disorder and obesity. Sleep disturbances are also commonly observed in these patients, yet the biological pathways which link sleep traits to the POGZ-associated syndrome remain unclear. We screened for sleep implications among individuals with causative POGZ variants previously described. Sleep disturbances were observed in 52% of patients, and being obese was not observed as a risk factor for sleep problems. Next, we identified genes associated with sleep-associated traits among the POGZ regulatory targets, aiming to uncover the molecular pathways that, when disrupted by POGZ loss of function, contribute to the aetiology of sleep phenotypes in these patients. The intersect between POGZ targets and sleep-related genes was used in a pathway enrichment analysis. Relevant pathways among these overlapping genes are involved in the regulation of circadian rhythm, tau protein binding, ATPase activator activity. This study may represent the beginning for novel functional investigations on shared molecular mechanisms between sleep disturbances and rare developmental syndromes related to POGZ and its regulatory targets.
In low-risk Myelodysplastic Syndrome (MDS), anemia is the major clinical problem and often represents the principal cause of symptoms which negatively influence quality of life (QoL). Moreover anemia has been associated with increased cardiac disease which, in older patients, may aggravate pre-existing conditions such as congestive heart failure. Patients with MDS often require red blood cell transfusions that further deteriorate patients' perception of well-being. This is an 18-month prospective observational investigation about the Quality of Life in Myelodysplastic patients with the aim to evaluate the correlation between hemoglobin (Hb) value and QoL and to compare the MDS patient's self-assessed QoL per physician's assessment. One hundred and fifty consecutive MDS patients at diagnosis and at least one with cytopenia - low level of hemoglobin or low level of neutrophils (a type of white blood cells that fights against infection) or low level of platelets (irregularly shaped cells found in blood that help prevent bleeding) - will be included in the evaluation. Demographic and disease-specific data will be collected and QoL will be evaluated by a specific questionnaire named QoL-E which will be completed both by patients and respective physicians. Study visits will be performed monthly until week 12; the subsequent visits will be performed at 6, 12 and 18 months. No Serious Adverse Event will be collected during the study, only adverse reaction to any Janssen-Cilag drug should be reported. This information may be important to optimize treatment according to patients' preferences and expectations, to detect functional complications, as well as to improve communication between patients and caregivers. Observational study - No study drug was administered.
Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
Suspected or confirmed new pulmonary tuberculosis cases who have received anti-tuberculosis drugs for less than 3 (three) days and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
Provided are an inhibitor, a prophylactic, and a therapeutic agent for rheumatoid arthritis that have no side effects and that can correct immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent for rheumatoid arthritis contain a  Euglena -derived material as an active ingredient. The inhibitor, the prophylactic and the agent are used as an antirheumatic drug for controlling the activity of rheumatoid arthritis by alleviating immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are also used for a living individual who has not been definitively diagnosed with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are continuously administered to the living individual from any point before definitive diagnosis of rheumatoid arthritis to any point after the definitive diagnosis. The  Euglena -derived material is at least one material selected from the group including  Euglena  algae, paramylon derived from the  Euglena , water-soluble amorphous paramylon prepared by treating the paramylon with alkali and neutralizing the treated paramylon, and emulsion paramylon prepared by ejecting a solution of the paramylon from a narrow bore nozzle at a very high pressure to cause the solution to collide with a collision surface.
BACKGROUND: Sepsis, a severe inflammatory response to infection, is a global health priority due to its high mortality and long-term disability rates. Its pathophysiology involves both inflammation and immune suppression. Managing sepsis requires significant healthcare resources and expenditure, with sepsis being a leading cause of hospital costs. Gut microbiotas play a crucial role in sepsis, and probiotics show promise in managing it by restoring microbial balance. Despite advances, targeted therapies for sepsis remain elusive, necessitating innovative approaches such as probiotic therapy.
METHOD: Fifty-four eligible patients with sepsis will be randomly assigned to either the synbiotic or placebo group. The synbiotic supplement, KidiLact, comprises ten probiotic strains and prebiotic fructooligosaccharides. Participants will receive two sachets daily for 7 days, mixed with sterile water and administered orally or via gavage. Inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) will be evaluated. Anthropometric measurements, nutritional assessment, biochemical analysis, and clinical evaluation will be conducted to assess treatment outcomes. Statistical analysis will be performed to compare results between the two groups, employing SPSS version 19 with a significance level of P < .05.
CONCLUSION: This randomized clinical trial aims to evaluate synbiotic supplementation effects on inflammatory markers and clinical outcomes in pediatric sepsis patients in the pediatric intensive care unit (PICU). Probiotics have shown promise in reducing proinflammatory cytokines like IL-6, TNF-α, and CRP, which are vital in the inflammatory response. Synbiotics can enhance gut integrity, preventing pathogen translocation and reducing inflammation. If our expectations regarding the effects of probiotics are correct, we can use them as a cost-effective supplement to improve the condition of pediatric sepsis in hospitals.
TRIAL REGISTRATION: IRCT,IRCT20230523058266N1 Registered 30 October 2023, https://irct.behdasht.gov.ir/trial/71397 .
PURPOSE: To provide antifungal agent showing strong antifungal action at a low concentration. CONSTITUTION: This antifungal agent contains an azole-based antifungal substance and lactoferrin as active ingredients. The azole-based antifungal substance is clotrimazole, ketoconazole, lanoconazole, itoraconazole or their mixture. The amount of lactoferrin contained is at least 100 pts.wt. based on 1 pt.wt. of the azole-based antifungal substance. Consequently, since the antifungal agent has strong antifungal effect with a small amount, it is useful as a therapeutic agent for various mycoses. The antifungal agent is safely usable as a means for suppressing abnormal breeding of a fungus of the genus Candida in a digestive organ. The antifungal agent has slight adverse effect and reduces the frequency of appearance of a resistant fungus.  The antifungal agent means can extremely reduce the amount of the azole-based antifungal substance by using it together with lactoferrin at a low concentration level not showing antifungal action.
Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].

Cardiovascular Disorders

In the clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo [see Warnings and Precautions (5.1)]. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo [see Warnings and Precautions (5.1)]. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women's Health Initiative (WHI) [see Warnings and Precautions (5.1)].
Elderly patients diagnosed with pneumonia after getting information and signing informed consent will be included in this trial. Simvastatin 20 mg will be administered to intervention group, while control group will receive placebo. Both groups will receive drugs (or placebo) for 30 days.

Baseline data will be collected within 24 hours after admission. Then the subject will be followed up for 30 days. At the 7th day, patients will be underwent several laboratory tests, i.e. serum TNF-α (Tumor Necrosis Factor alpha), IFN-ϒ Interferon gamma), CRP (C-Reactive Protein), and PAI-1 (Plasminogen Activator Inhibitor-1). Death from all causes until 30 days will be recorded.
Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with the virtual coach. They will get additional support from a clinical psychology trainee who provides therapeutic support that aims to enhance the usage of CBTi treatment strategies.
Continuous depth culture method for B.C.G. vaccine growth. Microbes, esp. mycobacterial, are grown by a continuous depth culture method. The method is used for the prodn. of vaccines and tuberculins, esp. B.C.G. anti-tuberculosis vaccine. The culture is performed in a stirred liquid phase in contact with an appropriate gaseous atmosphere; the liquid medium is passed around a closed circuit, and in part of the circuit it comes into contact with a reduced-pressure atmosphere. This causes rapid mixing of the gas and liquid phases, and breaks the froth. In another part of the circuit, medium and grown bacteria are removed and an equal amt. of fresh medium injected sterilely into the stream. This technique makes possible depth culture of B.C.G. bacillus, giving better yields.
PURPOSE:The titled pharmaceutical containing a citrate as a stabilizer. CONSTITUTION:A kallikrein pharmaceutical obtained by incorporating preferably 0.1-10wt% citrate, e.g. sodium citrate, as a stabilizer in kallikrein. The resultant pharmaceutical is useful for treating not only peripheral blood vessels but also various dermatopathies, e.g. scleriasis, Raynaud's syndromes or phlebocholosis, considered due to quasiperipheral angiopathy, and effective for treating cerebral hypometabolism. The dosage form thereof includes injection, tablet, external agent, etc. The amount of the kallikrein to be incorporated in the external agent is preferably 1-1,000 kallikrein units/g. The kallikrein to be incorporated in the oral agent or injection is preferably human urinous kallikrein, and the dose thereof is preferably 1-100 kallikrein units/g.
FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], and B/Yamagata \[B/Florida/4/2006\])a B strain of the Yamagata lineage.
The invention discloses a plant enzymolysis polypeptide and application thereof in repairing skin barrier damage and preparing skin repair cosmetics. The invention provides an enzymolysis polypeptide of isatis tinctoria seeds, and the molecular weight of the enzymolysis polypeptide is between 3000u and 5000 u. As is known to those skilled in the art, the skin barrier function is crucial to prevent skin damage caused by various external stimuli. After the skin barrier function is damaged, the barrier index is obviously reduced, the expression levels of key proteins FLG and LOR for maintaining the barrier function are reduced, and inflammatory symptoms are presented. The experiments show that the enzymolysis polypeptide provided by the invention can effectively resist skin barrier damage and effectively relieve various skin barrier damage indexes. Therefore, the enzymolysis polypeptide can be used for developing and preparing cosmetics for resisting skin barrier damage.
NEW MATERIAL:The compound of formula I (A is group of formula II or III; R<1> is group of formula IV-VI; R<2> and R<3> are H or OH). EXAMPLE:Digitoxigenin lactone. USE:A cardiotonic agent for the remedy of cardiac diseases such as congestive failure. It has extremely low side effects. PREPARATION:The objective compound can be prepared e.g. by dissolving the compound of formula VII in an organic solvent such as chloroform, adding preferably 1.2-1.5 time volume of an organic peracid (e.g. perbenzoic acid) to the solution, and carrying out the oxidation reaction preferably at 60-70 deg.C for 20min-24hr.
Adenovirus for use in anti-tumour therapy which has specificity for tumour cells, especially for tumour cells that have reduced activity levels of the tumour suppressor p53. It is known that the majority of tumours characteristically exhibit reduced activity of the tumour repressor p53. In tumour-bearing patients, the adenovirus provides for an effective cross-presentation of tumour antigens, which can be neoantigens, e.g. having low immunogenicity, and hence supports the induction of tumour-specific immune cells, especially of tumour-specific CD8 T- cells. Further, the adenovirus in tumour patients stimulates the non-specific immune response by NK-cells, preferably both locally and systemically, and the adenovirus improves migration of immune cells, e.g. T-cells, NK-cells, and antigen-presenting cells (APC), e.g. dendritic cells, into the tumour, and the adenovirus improves the maturation of immune cells, especially of APC, and improves the cytolysis of tumour cells by immune cells. The adenovirus has an E4 protein which contains an E4 orf4-encoded protein of one of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.
Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
PURPOSE: To obtain a preparation for the prolonged treatment and prevention of endoparasite and ectoparasite by dissolving an abermectin compound in a part of triacetin, adding the remaining triacetin to the obtained solution and sterilizing the product. CONSTITUTION: The objective preparation is produced by dissolving a compound of the formula II [R1 is present exclusively when the wavy line is a single bond and is H or OH; R2 is an alkyl or an alkenyl; R3 is OH or OCH3 =NOR5 (R5 is H or a lower alkyl); R4 is H, OH or a group of the formula III (R6 is OH, NH2 , a lower alkylamino, etc.)] (e.g. ibermectin or abamectin) in about 80vol.% of a compound of the formula I, dissolving an arbitrary antioxidation agent (e.g. n-propyl gallate, BHA or monothioglcerol) in the obtained solution at a concentration of 0.01-2.0% w/v, adding the remaining part of the compound of the formula I and sterilizing the product. The preparation produced by this process keeps its activity over a long period.
This group of participants will act as an attention control condition. This group will be asked to download the fitness application Strava to their smartphone, and track all of their runs and walks on Strava. Similar to the intervention group, participants will be provided with phone armbands to carry their phone during a run or walk so they can record the run or walk on Strava, and will be asked to try participating in 150 minutes of moderate-to-vigorous exercise per week.